Status:

COMPLETED

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Lead Sponsor:

UMN Pharma Inc.

Conditions:

Influenza

Virus Diseases

Eligibility:

All Genders

20-40 years

Phase:

PHASE2

Brief Summary

UMN-0501 is a purified recombinant influenza HA vaccine (A H5N1/Vietnam/1203/2004). The purpose of the present study is to evaluate immunogenicity, safety and optimal dose among three different doses...

Eligibility Criteria

Inclusion

  • Healthy adult as determined by medical history, physical examination, laboratory test, and clinical judgment of the investigator.
  • Males and females aged 20-40 years.
  • Provides signed informed consent form after received a detailed explanation of the study protocol prior to any study procedures.

Exclusion

  • Body Mass Index (BMI) 30 kg/m2 and above.
  • Has a history of a A/H5N1 influenza virus infection and subjects had received other A/H5N1 influenza vaccine.
  • Has a history of allergic reaction by food and medicine including vaccine, and acute fever illness (greater than 39.0C) within 2 days of vaccination.
  • Has a history of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM).
  • Has severe allergic diseases.
  • Has asthma.
  • Has a history of convulsions.
  • Has a history of any serious disease.
  • Known impairment of imune function.
  • Known rheumatism and autoimmune disease.
  • Receipt of medicines that would affect evaluation of immunogenicity.
  • Receipt of any live virus vaccination or receipt of any inactivated vaccine/toxoid prior to enrollment.
  • Blood donation prior to enrollment.
  • Receipt of another investigation agent prior to enrollment.
  • History of alcohol or drug abuse.
  • Females who are pregnant or potentially childbearing or are breastfeeding.
  • Ineligible subject based on the judgement of the investigator.

Key Trial Info

Start Date :

October 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2009

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT00980447

Start Date

October 1 2009

End Date

December 1 2009

Last Update

February 8 2010

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

National Hospital Organization Osaka Minami Medical Center

Kawachi-Nagano, Osaka, Japan, 586-8521

2

National Hospital Organization Tokyo Medical Center

Meguro-ku, Tokyo, Japan, 152-8902

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults | DecenTrialz